Among programs slated for elimination are ones disproportionately impacting LBGTQ people, including HIV prevention and ...

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now ...

GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand ...

In a first-ever milestone, Africa’s initial HIV cure trial has yielded historic findings: 20% of patients have remained off ...

An HIV patient in Laredo is sharing his advice with others living with the disease to raise awareness and highlight available ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

The US administration should clear up the confusion over the future of a widely admired AIDS fund and push for Congress to ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines.

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

Improving adherence to antiretroviral therapy (ART) in youth living with HIV requires interventions that target both family ...

In Zambia, truck drivers and sex workers have high rates of being HIV positive —- and are at high risk of contracting the ...